JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) said its Phase 3 Launch-HTN clinical trial evaluating lorundrostat was selected by JAMA editors as one of the most impactful medical studies …
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension Read More